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Identification of the genomic regions most intimately associated with non-Hodgkin's lymphoma 
(NHL) pathogenesis is confounded by the genetic heterogeneity of human populations. We 
hypothesize that the restricted genetic variation of purebred dogs, combined with the contrasting 
architecture of the human and canine karyotypes, will increase the penetrance of fundamental 
NHL-associated chromosomal aberrations in both species. We surveyed non-random aneuploidy 
in 150 canine NHL cases, revealing limited genomic instability compared to their human 
counterparts and no evidence for CDKN2A/B deletion in canine B-cell NHL. ‘Genomic recoding’ 
of canine NHL data into a ‘virtual human’ chromosome format showed remarkably few regions of 
copy number aberration (CNA) shared between both species; restricted to regions of dog 
chromosomes 13 and 31, and human chromosomes 8 and 21. Our data suggest that gene discovery 
in NHL may be enhanced through comparative studies exploiting the less complex association 
between CNAs and tumor pathogenesis in canine patients.
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Introduction
Non-Hodgkin's lymphoma (NHL) is among the most clinically and histopathologically 
diverse of all human cancers, characterized by an extensive range of morphologic and 
biologic subtypes that present challenges to diagnosis, clinical management and prediction 
of outcome. The identification of non-random DNA copy number aberrations (CNAs) in a 
wide range of human cancers has led to expanding interest in their utility as molecular 
markers for more comprehensive subclassification of distinct tumor subtypes and for 
development of therapeutic protocols targeted to specific mechanistic pathways (for 
example [1,2]). The identification of robust and clinically informative molecular indicators 
is, however, confounded by the extensive heterogeneity of human populations, within which 
the highly diverse and complex disease phenotypes observed are likely to have developed 
from a combination of multiple genetic risk factors, each with relatively weak penetrance. 
This is supported by numerous reports demonstrating that the extensive phenotypic variation 
in NHL is borne out by a high level of molecular heterogeneity (reviewed in [3]). The CNAs 
and associated genes that are most fundamentally associated with the disease pathogenesis 
have therefore remained largely elusive.
This challenge may be alleviated in part through parallel investigations of clinically and 
histologically comparable tumors in more genetically homogenous populations. The 
purebred domestic dog (Canis familiaris, CFA) represents a powerful spontaneous model 
for investigation of heritable risk and genetic factors that are clinically predictive in NHL, 
which accounts for up to 24% of all canine malignancies (for example [4]). As with its 
counterpart in human patients (hNHL), canine NHL (cNHL) displays extensive clinical and 
histological diversity and a growing need for more robust and informative subclassification. 
In the domestic dog, however, the likely confounding effects of genomic heterogeneity are 
limited as a consequence of the strategic development of distinct and genetically isolated 
populations in the form of >350 discrete and intensively regulated breeds, each exhibiting 
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restricted genetic and phenotypic diversity (reviewed in [5] and others). Thus, detection of 
the genetic factors that are most intimately associated with tumor predisposition and 
pathogenesis may be more penetrant and in turn, more evident, in these relatively 
homogenous purebred canine populations as compared to human patients with the 
equivalent disease.
The relative incidence of cNHL is approximately five-fold greater than that of hNHL [4,6]. 
This is due in part to the significantly increased prevalence of naturally-occurring lymphoma 
in many of the most popular family-owned dog breeds, whose distinct temporal, 
geographical and phylogenetic origins are well described [7,8]. Furthermore, there is 
striking variation in the relative prevalence of B- and T-cell-derived lymphoproliferative 
disease in different breeds [9]. For example, the incidence of B-cell lymphoma (BCL) versus 
T-cell lymphoma (TCL) in the Labrador Retriever is similar to that observed when 
considering all dog breeds as one common population (65% BCL:35% TCL). The Golden 
Retriever, however, shows approximately equal incidence of both BCL and TCL (54% 
BCL: 46% TCL), while in the Boxer the majority of NHL cases comprise TCL (estimated to 
be as high as 65%) [9-11]. This breed-related susceptibility, combined with evidence for 
familial clusters of cNHL in purebred dogs [12,13] is strongly suggestive of an intimate link 
between NHL pathogenesis and genetic factors [4,11]. The unique characteristics of cNHL 
populations thus offer alternative means to identify the subset of shared genomic aberrations 
that are likely to be most intrinsic to tumor pathogenesis, using the dog to ‘filter out the 
background noise’ that continues to confound hNHL studies. Furthermore while the human 
genome is organized into 23 pairs of metacentric, submetacentric and acrocentric 
chromosomes ranging from 247Mb to 47Mb in size, the 39 chromosome pairs comprising 
the domestic dog karyotype are almost exclusively acrocentric/telocentric, ranging in size 
from just 125Mb to 26Mb [14]. The vastly contrasting architecture of the human and 
domestic dog karyotypes allows the two genomes to be evaluated in the context of the 200+ 
evolutionarily conserved chromosome segments from which they are both configured [15]. 
We propose that this will aid identification of those cytogenetic aberrations that represent 
intrinsic features of the disease, rather than a consequence of species-specific structural 
genomic organization.
We present the first genome-wide survey of tumor-associated CNAs in cNHL through array-
based comparative genomic hybridization (aCGH) analysis of 150 naturally occurring cases 
in purebred dogs. The study population targeted three of the six most popular dog breeds 
within the US [16], the Golden Retriever, Labrador Retriever and Boxer, due to their 
elevated predisposition to NHL and contrasting incidence of BCL and TCL subtypes [7]. 
Canine aCGH data were ‘recoded’ into human genome format, enabling direct comparison 
with existing data from human patients. This comparison provided evidence for a marked 
reduction in genomic instability in canine NHL as compared to the human counterpart, and 
we discuss these findings in context with the structural configuration of their genomes. 
These data highlight the limited subset of CNAs that are evolutionarily conserved between 
human and canine NHL, which may harbor disease-associated genes and hereditary risk 
factors that have remained beyond the limits of detection when evaluated solely within 
human populations.
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Histopathology Evaluation of the Canine Lymphoma Cohort
Clinical specimens were recruited between 2003 and 2009 from community or institutional 
veterinary practices, from client-owned dogs with clinical signs consistent with lymphoma. 
Specimens were acquired prior to initiation of therapy and under approved protocols with 
informed client consent. Representative lymph node biopsies were formalin-fixed and 
paraffin-embedded for histological evaluation. A diagnosis of lymphoma was confirmed by 
examination of hematoxylin and eosin (H&E)-stained sections in conjunction with 
conventional immunohistochemical techniques using CD3 and CD79a markers. Standard 
morphological features were used to define the histological subtype, grade and mitotic index 
of the tumor based on the World Health Organization (WHO) classification system for 
human lymphoid neoplasia [17], which has been shown to be translatable to the canine 
counterpart with a high degree of accuracy and reproducibility [18]. Histological specimens 
were reviewed independently by two or more board-certified veterinary pathologists, one of 
whom (VEV) was common to all cases, to maximize consistency. Patient details and 
histological classifications of all 150 cases are provided as supplementary online materials 
(SOM table I) and are summarized in figure 1. Overall 71.3% of the 150 cases evaluated 
were derived from the three target breeds, the Golden Retriever (GR, 68 cases), Labrador 
Retriever (LR, 27 cases) and Boxer (12 cases) (figure 1a). The remaining 43 (28.7%) cases 
were represented by 18 ‘other’ breeds, with between one and five individuals per breed. The 
cohort comprised 113 BCL tumors (75.3% of cases) and 37 TCL tumors (24.7% of cases). 
The distribution of cases by histological subtype is shown in figure 1b (insufficient tissue 
availability precluded definitive subtype classification of 11 cases). Overall 67.7% were 
high-grade tumors, 26.6% were low-grade tumors and the remaining cases were of 
intermediate grade. The average age at diagnosis across all cases was 7.5 years (median = 7 
years, range 2 – 14 years, nine cases were of unspecified age).
Microarray-Based Detection of Tumor-Associated CNAs
DNA was isolated from representative tumor tissue using a Qiagen DNeasy Kit (Qiagen, 
Valencia, CA). aCGH analysis was performed using a custom microarray comprising 
cytogenetically-mapped bacterial artificial chromosome (BAC) clones from the CHORI-82 
dog library (http://bacpac.chori.org, BACPAC Resources, Children's Hospital Oakland 
Research Institute, Oakland, CA). The array comprises clones distributed at approximately 
1Mb intervals throughout each dog autosome and the X chromosome (mean interval 
1.10Mb, range 0.28Mb to 3.28Mb), in addition to clones representing canine orthologues of 
53 human genes associated with a range of cancers [19]. Locations of BAC clones are 
denoted herein according to their cytogenetic location and then their Mb position on that 
chromosome, based on the canFam v2.0 (May 2005, [20]) dog genome sequence assembly 
(for example, CFA 1q11; 3.2Mb). Canine aCGH analysis was performed as described 
previously [19]. Microarrays were scanned at 5μm resolution using an Agilent G2565CA 
scanner and image data were processed using Feature Extraction version 10.7 (Agilent 
Technologies, Santa Clara, CA). Signal intensity data were block normalized, and arrayed 
loci with confidence estimates < 0.5 and/or replicates with standard deviation > 0.3 were 
excluded from further analysis. Data visualization and statistical analysis were performed 
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using Genomic Workbench version 6.0 (Agilent Technologies) using the ADM1 calling 
algorithm with a threshold of four and a fuzzy zero correction. Parameters for genomic copy 
number gains and losses were set at log2 tumor DNA signal intensity:reference DNA signal 
intensity of +/− 0.2. Recurrent CNAs were defined as those identified in ≥20% of cases 
analyzed. Correlation between individual CNAs and signalment/diagnostic parameters was 
explored by converting log2 ratio data to ordinal values (gain/normal/loss) and performing 
Mantel-Haenszel Chi square tests to identify significant associations (p < 0.05). A 
Bonferroni correction was applied by deriving a p-value threshold for significance based on 
the number of arrayed genomic loci assessed in these comparisons, in order to correct for 
multiple testing and to control family-wise error rates, resulting in a cut-off for statistical 
significance at p < 2.181 × 10−5. Predictive modeling was performed for statistically 
significant regions using logistic regression and multiple regression analysis. Statistical 
analysis was performed with Stata v.11 (www.stata.com).
‘Genomic Recoding’ of cNHL Data and Comparison with hNHL data
Canine aCGH data were recoded into ‘virtual’ human genome format in order to facilitate 
direct visual comparison of cytogenetic profiles of human and canine NHL. Briefly, the 
positional co-ordinates of each arrayed canine clone were defined according to the 
nucleotide location of paired BAC end sequence data within the canine genome sequence 
assembly (http://genome.ucsc.edu, canFam v2.0, May 2005, [20]). These data were imported 
into the Liftover Batch Coordinate Conversion Tool (http://genome.ucsc.edu/cgi-bin/
hgLiftOver), using default settings to establish the orthologous nucleotide sequence 
coordinates for arrayed canine BAC clones within the human genome sequence assembly 
(February 2009, GRCh37/hg19). Tumor:reference signal intensity data at each arrayed locus 
for each cNHL case were then replotted according to these ‘virtual’ human chromosome 
locations.
Raw datasets were retrieved for prior BAC-array CGH studies of hNHL [21-23] (Masao 
Seto, Masao Nakagawa and Ichiro Takeuchi, pers. comm.), which utilized a 1.3Mb-
resolution BAC-array platform comparable to that used in the present study for cNHL. 
These studies reported cytogenetic profiling data for 46 human nodal diffuse large B-cell 
lymphoma (DLBCL) cases [21,22] and 29 human nodal peripheral T-cell lymphomas 
(unspecified, PTCLu) cases [23], respectively and are consistent with additional studies 
using similar analysis platforms and techniques [21,24,25]. Raw log2 test:reference signal 
intensity data [21-23] were processed using the same parameters used for canine cNHL data. 
Human and canine data were then plotted on a common axis according to the location of 
arrayed BAC sequences within the GRCh37/hg19 human genome sequence assembly, 
enabling direct visual comparison of aCGH data for the same tumor type in both species.
Extended aCGH Analysis of Selected cNHL Cases at Higher Resolution
Five cNHL cases from the cohort were analyzed further using a ∼180,000-feature canine 
oligonucleotide CGH microarray (Agilent Technologies), comprising repeat-masked ∼60-
mer oligonucleotides distributed at approximately 13kb intervals throughout the dog genome 
sequence assembly. Tumor and reference DNA samples were labeled independently with 
Cyanine3-dUTP and Cyanine5-dUTP, respectively, using the Genomic DNA Enzymatic 
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Labeling Kit (Agilent Technologies). Oligonucleotide-array CGH (oaCGH) analysis was 
performed following the manufacturer's recommendations. Arrays were scanned at 3μm 
resolution using an Agilent G2565CA scanner and image data were processed using Feature 
Extraction version 10.7 and Genomic Workbench version 6.0 (Agilent Technologies). Data 
were filtered to exclude probes exhibiting non-uniform hybridization or signal saturation and 
were normalized using the centralization algorithm with a threshold of six. The ADM2 
algorithm was used to define CNAs using a ‘three probes minimum’ filter and a threshold of 
six with a fuzzy zero correction.
Results
Genome-Wide Overview of Recurrent CNAs in cNHL
Data analysis proceeded through successively focused evaluation, commencing with a 
genome-wide overview of CNAs within all cNHL cases studied, followed by locus-specific 
comparisons at the level of tumor phenotype and histological subtype, and finally by breed. 
The global level of genomic instability in cNHL was markedly less extensive than that 
observed in similar studies of canine osteosarcomas (Angstadt et al., submitted) and 
histiocytic tumors (Hedan et al, manuscript in preparation), and was more comparable to 
that of canine intracranial tumors [26], with a limited proportion of the genome involved in 
highly recurrent copy number imbalance, few apparent homozygous deletions and no high 
level amplifications. Figure 2a presents a genome-wide penetrance plot summarizing the 
frequency and distribution of DNA copy aberrations at ∼1Mb intervals within the cohort of 
150 cNHL cases. These data show that aneuploidy in cNHL was restricted predominantly to 
copy number increase along the length of CFA 13 and 31. No chromosomes showed a 
combination of both recurrent gains and losses among the cohort, indicating that individual 
CNAs were primarily unidirectional. Data for all 150 tumors were stratified into cBCL cases 
(n = 113) and cTCL cases (n = 37) to summarize the relationship between 
immunophenotype and genome-wide DNA copy number imbalance. Figure 2b shows that 
recurrent CNAs in cBCL consisted primarily of gains along CFA 13 and 31 and partial loss 
of CFA 26, with the remainder of the genome showing minimal evidence for imbalance. 
cTCL showed a higher frequency and wider distribution of recurrent CNAs (figure 2c), 
including gains of CFA 6, 9, 13, 20, 29, 31 and 36, and losses of CFA 11, 17, 22, 28 and 38, 
the majority of which extended along most of the length of the chromosome. These data 
indicate that while gains of CFA 13 and 31 are shared features of both phenotypes, the 
majority of the genomic imbalance observed within the cNHL cohort (figure 2a) is driven by 
cTCL. Regions of recurrent CNA in cBCL and cTCL are detailed in SOM table II and 
example data from BAC-array CGH analysis are provided in SOM figure 1.
Identification of CNAs Associated with Tumor Immunophenotype
Bonferroni-corrected chi-square analysis of aCGH data from of the entire cohort of 150 
cNHL cases identified 134 arrayed BAC clones representing genomic regions that showed a 
significant difference in DNA copy number status in cBCL compared to cTCL (SOM table 
III). These loci were distributed across 23 different chromosomes, of which 11 were 
represented by a single BAC clone, consistent with a CNA ∼2Mb in size. The most 
extensive region of significant association encompassed 45 clones distributed along the 
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length of CFA 11, extending from ∼9.5Mb below the centromere down to the most 
telomeric clone at 77.0Mb. Deletion of this ∼67.5Mb region was associated significantly 
with cTCL and peaked at the CDKN2A/B tumor suppressor gene locus at CFA 11q16; 
44.3Mb (p < 2.90 × 10−15). Copy number loss of CDKN2A/B occurred in 20/36 cTCL cases 
(55.6%), and was more frequent in high-grade cTCL (10/15 cases) versus low-grade cTCL 
(2/6 cases), but was not evident in any of the 111 cBCL cases scored at this locus. Also 
associated significantly with cTCL was copy number gain of a 39.2Mb region spanning the 
length of CFA 29 (3.2 - 42.4Mb), as well as losses along CFA 17 and 38, and gains along 
CFA 20 and 36 (SOM table III).
The reduced level of aneuploidy in cBCL relative to cTCL (figure 2) was supported by the 
identification of few regions of association between tumor phenotype and DNA copy 
number status within cBCL. In contrast to the recurrent losses along the length of CFA 11 in 
cTCL, the CNA associated most significantly with cBCL was highly recurrent deletion of a 
discrete ∼2Mb region on CFA 26q24:28.6–30.4Mb (peaking at 30.4Mb, deleted in 69.8% of 
cBCL cases scored [74/106 cases], p < 2.59 × 10−14). This deletion encompasses the canine 
immunoglobulin lambda locus (IGLλ) and flanked both proximally and distally by normal 
copy number. Deletion of this region was not evident in any cTCL cases.
Since deletions of CFA 11q16; 44.3Mb and CFA 26q24; 30.4Mb were restricted to cTCL 
and cBCL, respectively, in the present study, we assessed their potential value as molecular 
indicators of tumor immunophenotype in cNHL. Predictive modeling by regression analysis 
showed that when assessed in combination, determination of the copy number status of these 
two regions alone predicts the cBCL phenotype with 93.8% accuracy, and predicts the cTCL 
phenotype with 59.5% accuracy, with an overall accuracy of 85.3%. Full details of this 
analysis are provided in SOM Appendix 1.
Evidence for CNAs Associated with Histological Subtype
Based on the extensive variation observed between the genomic profiles of cBCL and cTCL, 
all subsequent comparisons were stratified by tumor phenotype. Within each tumor 
phenotype we assessed whether genomic copy number aberrations were significantly 
associated with histological subtype. The two most highly represented cBCL subtypes, 
DLBCL (80 cases) and marginal zone lymphoma (MZL, 16 cases), showed negligible 
variation in DNA copy number status, with no significant differences in their genomic 
profiles. cTCL subtypes also showed highly conserved profiles; however four loci (two on 
CFA 29 and one each on CFA 7 and X) showed a significantly elevated incidence of copy 
number gain in PTCLu (n = 18 cases) as compared to T-zone lymphoma (TZL, n = 8 cases). 
These regions are defined in SOM table IV. There was no evidence for significant 
differences in CNA status based on tumor grade.
Evidence for CNAs Associated with Breed
We investigated evidence for genomic regions whose copy number status was associated 
significantly with the breed of the patient, which might be indicative of heritable risk of 
disease within a consistent genetic background. This analysis was restricted to the three 
target breeds and was stratified by phenotype. No significant correlations were found within 
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cBCL, and the disproportionate distribution of high p-values suggested that cBCL in 
different breeds show highly conserved genomic copy number status (SOM table V). In 
contrast, cTCL showed a skew towards low p-values, suggesting that the cytogenetic 
profiles of tumors of this phenotype may be more strongly influenced by the genetic 
background of the patient as compared to cBCL. Seven individual loci (on CFA 6, 12, 20 
and 31) showed highly significant association with breed, each demonstrating an elevated 
incidence of copy number gain in Boxers with cTCL (SOM table V).
Comparative analysis of cNHL and hNHL by genomic recoding
Of the 2143 arrayed canine BAC clones evaluated using the Liftover Batch Coordinate 
Conversion Tool, 2083 (97.2%) were converted successfully to a unique orthologous 
position in the human genome sequence assembly. Canine sequence data for 42 clones 
intersected with multiple regions of human sequence and for the remaining 18 clones no 
orthologous human chromosome sequence could be identified. These 60 clones were 
excluded from subsequent genomic recoding and comparative evaluation. With DLBCL 
being the most highly represented and investigated form of NHL in both species, and 
representing more than half of the cohort in the present study, we focused on this subtype as 
the basis for extended assessment of evolutionarily conserved CNAs. Figure 3a presents, in 
conventional canine genome format, a genome-wide penetrance plot of BAC CGH data for 
the 80 cDLBCL cases from the present study, demonstrating the limited aneuploidy 
associated with the histological subtype in canine patients. The most extensive and highly 
recurrent CNAs, gains of CFA 13 and 31, are highlighted in blue and pink, respectively. 
Recurrent gain of the MYC oncogene and absence of deletion of the CDKN2A/B tumor 
suppressor gene locus are also indicated, determined by the copy number status of arrayed 
canine BAC clones encompassing these genes [19]. Figure 3b presents the same cDLBCL 
data from figure 3a, now recoded into ‘virtual human genome format’ to facilitate cross-
species comparisons. The human genomic regions orthologous to CFA 13 and 31 are 
highlighted, demonstrating that if CNAs of these chromosomal regions were conserved in 
hDLBCL patients, they would manifest as gains of HSA 8qdist/4pprox-qprox (blue shading) 
and HSA 21 (pink shading), respectively. Figure 3c shows the genome-wide penetrance plot 
for 46 hDLBCL cases that were evaluated using a 1.3Mb-resolution human BAC aCGH 
platform [21,22], demonstrating a wide range of aneuploidy distributed across the human 
karyotype. Comparison of these data with figure 3b reveals that hDLBCL exhibits a 
substantially elevated incidence of detectable genomic imbalance compared to cDLBCL, 
and unlike its canine counterpart, presents with recurrent CDKN2A/B deletion. Comparison 
of the highlighted chromosome regions in figures 3b and 3c show that while copy number 
increase of HSA 4pprox-qprox is infrequent in hDLBCL there is evidence for shared gain of 
CFA13q/HSA8q (including MYC) in both species and, to a lesser degree, of CFA31q/
HSA21q.
Takeuchi et al [22] classified all 46 hDLBCL cases evaluated by aCGH into one of two 
molecularly distinct variants, the activated B cell-like [ABC] form (28 cases) and the 
germinal center B cell-like [GCB] form (18 cases). Figures 3d and 3e, respectively present 
data from these 46 human cases now subdivided according to these variants. To our 
knowledge there is no firm evidence thus far to indicate whether these variants exist in 
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cDLBCL. We therefore investigated whether cDLBCL data exhibited shared CNAs 
consistent with these tumor subtypes. Based on the lack of CDKN2A/B deletion in cDLBCL 
(equivalent to loss of HSA 9p21, a characteristic of hABC-DLBCL), and the conservation in 
cDLBCL of key CNAs associated with the GCB form in human patients (gain of MYC at 
CFA 13q13/HSA 8q24, and gain of CFA 31/HSA 21) [21,25], the present study provides 
preliminary support for an elevated representation of the GCB-form of cDLBCL.
A similar assessment was performed for the most common cTCL subtype within the present 
study, PTCLu (48.6% of all cTCL cases evaluated). Figure 4 shows a genome-wide 
penetrance plot for 18 cPTCL cases in canine (figure 4a) and in recoded human genome 
format (figure 4b). These data recapitulate the elevated degree of aneuploidy associated with 
cTCL as compared to cBCL (compare figures 2b and 2c), and demonstrate recurrent gain of 
MYC and deletion of CDKN2A/B in cPTCLu. Figure 4c presents data for 29 hPTCLu cases 
from a prior BAC-aCGH study [23]. Compared to observations from DLBCL in figure 3, 
comparison of figures 4b and 4c show a more comparable degree of genome-wide 
aneuploidy in PTCLu in both species. Furthermore, unlike in DLBCL, PTCLu tumors 
exhibit conserved deletion of CFA 11/HSA 9p, peaking in incidence at the CDKN2A/B 
locus. In support of our hypothesis, the penetrance of CDKN2A/B deletion relative to the 
copy number status of its flanking regions, was markedly elevated in canine patients. Figure 
4 indicates additional CNAs in hPTCLu that are conserved in the dog counterpart, including 
loss of HSA10q and 13q, and gain of HSA 1q, 3, 4, 8q (including MYC), 16p and 17q. In 
contrast, deletions of HSA 6q, 12q and 16q and gains of HSA 7 and 11 did not appear to be 
conserved in the canine counterpart.
Extended Analysis of cDLBCL by Oligonucleotide aCGH (oaCGH)
Five high-grade cDLBCL cases from the cNHL cohort were analyzed further by oaCGH 
analysis to assess evidence for the presence of additional CNAs that lay below the detection 
limits of the BAC array platform. These cases were selected as representative examples of 
the BAC aCGH profiles identified within this most highly abundant histological subtype 
evaluated in the study. The aCGH profiles from both array platforms for each case are 
compared in SOM figure 1, showing that the limited aneuploidy identified by BAC aCGH 
was recapitulated by the higher-resolution oaCGH platform, which also verified the 
balanced copy number status of CDKN2A/B in these cases (SOM figure 2). A total of 22 
CNAs were shared by two or more of the five DLBCL cases evaluated by high-resolution 
oaCGH, of which two represented full length gains of CFA 13 and 31 (SOM table VI). The 
remaining 20 shared CNAs were distributed across 12 different chromosomes and were each 
< 8Mb in size, including eight regions that were < 0.5Mb and a further four that were < 
65kb.
Discussion
Genomic Recoding Facilitates Direct Comparison of Cross-Species aCGH data
We proposed that genome-wide comparison of CNAs in canine and human NHL would aid 
definition of shared karyotypic features that are intimately involved in disease pathogenesis. 
Genomic recoding of canine aCGH data and direct comparison with existing human datasets 
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(figure 3) supported our hypothesis that much of the complexity evident in cytogenetic 
profiling of hDLBCL may be associated with the greater degree of natural genomic 
heterogeneity inherent to human populations, masking the genetic factors that are most 
fundamentally associated with tumor pathogenesis. The similarity between the array 
platforms and analysis techniques used, coupled with shared histological classification 
criteria, suggest that, at the chromosomal level, the limited aneuploidy associated with 
cDLBCL is sufficient to result in a comparable phenotype to that of hDLBCL, which 
presents with considerably more extensive genomic instability. The conserved copy number 
increase of two orthologous subchromosomal regions in human and canine patients, despite 
their extensively divergent genome architecture, now highlights CFA 13q11-q21.1 
(3.4-40.9Mb)/HSA 8q22-qtel (99.2-145.7Mb) and CFA 31q11-qtel (14.2-39.9Mb)/HSA 
21q11-qtel (15.6-44.9Mb) with elevated evidence for harboring genes that are 
fundamentally involved in tumor pathogenesis, including the MYC oncogene. Further 
interrogation of these regions identifies additional genes that have been associated 
previously with human lymphoproliferative disease including OLIG2 (oligodendrocyte 
lineage transcription factor 2, HSA 21q22,1), ERG (v-ets erythroblastosis virus E26 
oncogene like, avian, HSA 21q22.3), RUNX1 (runt-related transcription factor 1, HSA 
21q22.3), CHIC2 (cysteine-rich hydrophobic domain 2, HSA 4q11-q12), KDR (vascular 
endothelial growth factor receptor 2, HSA 4q11-q12) and KIT (v-kit Hardy-Zuckerman 4 
feline sarcoma viral oncogene homolog, HSA 4q12) [27-29] and others. Extended analysis 
using high-resolution oaCGH suggested that the limited complexity apparent in cDLBCL 
remained evident even at 50-fold higher resolution, but also identified several 
microdeletions/amplifications in cNHL that could not be detected using BAC aCGH 
analysis (SOM table VI), and which will be pursued in future studies. Despite its devastating 
impact, there are remarkably few comprehensive reports of high-resolution cytogenetic 
profiling in defined hNHL cohorts beyond the most common histological subtypes; thus it 
remains to be seen whether these ‘microaberrations’ are also evident in human patients, and 
what their biological relevance may be.
Gene expression profiling and immunohistochemical studies have shown previously that 
hDLBCL comprises at least two common and molecularly distinct variants (reviewed in 
[30]). While they share extensive overlap in histology, the GCB subtype is typically less 
aggressive and associated with a more favorable prognosis compared to ABC tumors; thus 
subclassification may be of clinically predictive value. Furthermore, previous studies have 
shown that ABC-DLBCL and GCB-DLBCL tumors in human patients exhibit variation in 
their genomic profiles, with a subset of CNAs (summarized in figures 3d and 3e) being 
strongly associated with one or other subtype [21,22,24,31-38]. It is not yet clear whether 
these distinct variants exist in cDLBCL. Although data from the present study provided 
preliminary support for CNAs consistent with the GCB form, the limited aneuploidy 
detected in cDLBCL precludes more detailed conclusions.
Comprehensive gene expression profiling and high-resolution aCGH analysis of a common 
cohort may be required in order to provide more robust and comprehensive evidence for 
molecular variants in cDLBCL. Figure 3 does, however, suggest that the extensive variation 
in the cytogenetic profiles of canine and human DLBCL cohorts is not attributable solely to 
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differential representation of ABC and GCB variants. The potential value of discrimination 
between ABC-DLBCL and GCB-DLBCL in the purebred dog is supported further by 
knowledge that the frequency and distribution of these variants, and their associated 
chromosome rearrangements and gene dysregulation events, varies greatly between different 
human populations and ethnic backgrounds [39].
Immunoglobulin Gene Deletions in cBCL
Subchromosomal deletion of CFA 26 was a hallmark event in cBCL that does not appear to 
be conserved in hBCL. Although several cancer-associated loci (NF2, BCR, PTEN) are 
located within CFA26qdist, our prior studies using metaphase chromosome-based CGH [40] 
suggested that extensive imbalances (>5-10Mb in size) of CFA 26 were not highly recurrent 
in cNHL. The increased resolution capabilities of the aCGH analysis platforms used in the 
present study now define a highly recurrent deletion of <2Mb within CFA 26q24: 
28.7-30.4Mb that was restricted to cBCL, encompassing the canine IGLλ gene. Deletions of 
immunoglobulin light chain loci are common events in hBCL, arising from clonal gene 
rearrangement during formation of a functional B-cell receptor in mature lymphocytes. 
Using BAC aCGH in hBCL Tagawa et al [21] identified a high frequency of localized 
deletion of the immunoglobulin light chain kappa locus (IGLK, HSA 2p11), while there was 
no evidence for recurrent deletion of IGLλ (HSA 22q11). This is contrary to the findings of 
the present study of cBCL, in which we observed a high incidence of deletion encompassing 
IGLλ (74/106 cases scored) and limited evidence for recurrent IGLK deletion (16/103 cases 
scored, CFA 17q16: 40.7Mb). CGH analysis revealed that the common deletion 
encompassing the canine IGLλ region lay close to the limit of detection of our ∼1Mb-
resolution BAC-array platform; thus these contrasting findings may simply reflect the 
specific nature and genomic coverage of the arrayed targets in this and prior studies of 
hBCL by BAC-aCGH. The pattern of IGLλ versus IGLK deletion in cBCL was, however, 
supported by subsequent application of high-resolution oaCGH analysis to a subset of the 
cohort. While in humans the ratio of light chain usage in immunoglobulin formation is 
relatively balanced (60% IGLK, 40% IGLλ) [41], prior studies in the domestic dog have 
attributed approximately 90% of light chain usage to IGLλ [42]. Our aCGH data support 
these findings, suggesting that clonal rearrangement of immunoglobulin light chains is more 
likely to manifest as recurrent deletion of IGLK in hNHL and of IGLλ in cNHL. The region 
corresponding to the immunoglobulin heavy chain (IGH) locus (CFA 8q33.3; 76Mb) is 
minimally annotated in the canFam2 genome assembly, with an apparent gap in coverage 
spanning 0.3Mb that encompasses the predicted location of the dog IGH locus. The limited 
annotation of this chromosome region and the absence of BAC clones encompassing the dog 
IGH locus precludes complete analysis of the structural and numerical status of this region 
at the present time.
Unlike hDLBCL, most other forms of hBCL have received little attention at the genomic 
level, in part due to the relative paucity of these subtypes in human populations. Nodal 
marginal zone lymphoma is infrequent in human patients but is the most common indolent 
BCL subtype in canine populations [18,43]. Conversely classical Burkitt's like lymphoma, 
while relatively common in people, is considered not to exist in the dog, and both the variant 
Burkitt's-like lymphoma and follicular lymphoma also are rare in canine populations [18]. 
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Mantle cell lymphoma is infrequent in both species. A comparative approach would provide 
an opportunity to combine these limited canine and human clinical resources into more 
extensive and synergistic datasets, increasing the power to define clinically informative 
molecular indicators for less common BCL subtypes.
Comparative Analysis of Canine and Human TCL
Similar opportunities are presented by virtue of the elevated incidence of TCL in canine 
versus human populations, and their contrasting relative incidence of specific TCL subtypes 
[4]. Data from the present study revealed more complex and extensive genomic instability in 
cTCL as compared to cBCL, consistent with their human counterparts (for example, [44]). 
Cytogenetic investigations of hTCL have focused largely on extranodal forms due to their 
relative abundance over nodal hTCL [6,45]. Histological classification of nodal hTCL is 
complex and somewhat controversial, and there is limited knowledge of genomic 
characteristics that are highly associated with individual subtypes. Anaplastic large cell 
lymphoma (ALCL) is among the more common hTCL subtypes (∼15% of all hTCL cases 
[45]) and has received moderate cytogenetic characterization, but is uncommon in the dog 
(<2% of cTCL, [18]). Conversely T-zone lymphoma (TZL) is common in the dog 
(representing 37% of all cTCL [18] and 22% of cTCL cases in the present study) but is so 
infrequent in human populations [4,45] that virtually no information exists regarding their 
genomic characteristics. Moreover the TZL subtype was eliminated from the most recent 
WHO classification of human lymphoproliferative disease due to extensive biologic and 
microscopic overlap with other indolent forms of hTCL [46], confounding direct correlation 
between human and canine tumors. The most promising candidates for comparative studies 
are the ‘peripheral T-cell lymphomas- unspecified’ (PTCLu), which represent ∼ 60-70% of 
hTCL cases in Western countries [47] and ∼ 40-50% of cTCL [18]. In both species PTCLu 
comprises a histologically, clinically and molecularly heterogeneous group of tumors whose 
characteristics do not fit within any defined entity in the WHO Classification system. This 
heterogeneity is recapitulated in the typically chaotic and variable cytogenetic profiles of 
hPTCLu [23,48-50], which was consistent with our observations for cPTCLu in the present 
study (figure 4). Unlike in DLBCL, canine and human PTCLu exhibit shared deletion of the 
CDKN2A/B tumor suppressor gene, a CNA that was more common in high-grade cTCL 
versus low-grade cTCL. This was consistent with our prior functional studies of high-grade 
cTCL [4,9,40,51], which identified a consequent increase in the proportion of tumor cells 
showing hyperphosphorylation of Rb, which is regulated by p16. Low-grade/indolent cNHL 
rarely showed inactivation of the p16/Rb pathway, although Rb phosphorylation was also 
observed infrequently in high-grade cBCL. We suggested that this may be a consequence of 
upregulation of MYC in cBCL through gain of CFA 13 or IGH/MYC fusion rather than 
disruption of the p16 pathway [4,51], which correlates with the absence of CDKN2A/B 
deletion in cBCL in the present study. Furthermore, the absence of detectable CDKN2A/B 
deletion in cBCL invites further examination of the functional role of this tumor suppressor 
gene in the pathogenesis of the clinical and histological counterpart in human patients.
Figure 4 suggests that there is greater conservation in the genomic profiles of canine and 
human TCL as compared to BCL, although this is likely to be at least in part a consequence 
of the elevated level of aneuploidy in cTCL. Interestingly the pattern of genomic gain and 
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loss along the length of several chromosomes within the cohort of human patients was also 
remarkably similar in recoded canine PTCLu data, but the relative incidence of these 
imbalances was elevated in the canine cohort. For example, both species present with 
recurrent loss of HSA 8p compared to gain of HSA 8q, an elevated incidence of gain of 
HSA 9qdist compared to HSA 9qprox and a greater incidence of HSA 13q gains towards the 
telomeric region of this chromosome, but these aberrations are more frequent within the 
recoded data for the canine NHL population (figure 4b and c). This adds support to the 
hypothesis that tumor-associated CNAs may be more penetrant in canine populations.
A region of deletion of HSA 5q (peaking at 5q21) has been strongly associated with hTCL 
and the hPTCLu subtype in particular, with a possible correlation with longer survival in 
European populations [48]. There is evidence for conservation of this aberration in our 
cTCL cohort (figure 4b, consistent with deletion of CFA 11). Interestingly, however, figure 
4c shows that this CNA was not evident in the study of hPTCLu in Japanese patients by 
Nakagawa et al. [23]. This may be attributable to the contrasting geographical and/racial 
distribution of the hPTCLu cohorts [23] or to differential exposure of these populations to 
pathogenic viruses (reviewed in [52]). This represents an example of the likely confounding 
effects of genetic heterogeneity in human populations that may be overcome by studies of 
purebred dogs for which genetically isolated populations are readily available for focused 
study.
Figure 4 shows that one of the most common CNAs in hPCTL, gain of HSA 7, was not 
conserved in cPTCLu. While gain of HSA 7q is frequently observed in hPTCL, this 
aberration is also common in a wide range of other human neoplasms, and there is evidence 
that it may represent a secondary abnormality acquired during tumor progression [49]. 
Similar circumstances may apply to gain of CFA 13, which was by far the most frequent 
aberration detected in the present study, resulting in copy number increase of the MYC 
oncogene (CFA 13q13) in 36.7% of the entire cNHL cohort (55/150 cases). This gene has 
received considerable attention in hBCL patients due to the high frequency of aberrant 
fusion events with immunoglobulin gene loci, resulting in transcriptional dysregulation and 
constitutive expression of MYC (reviewed in [37,53-55]). Conventional aCGH analysis is 
considered blind to chromosome aberrations that do not result in net DNA gain or loss, and 
therefore cannot detect balanced translocations. It is becoming increasingly evident, 
however, that many translocation events described in human cancers involve deletions and 
amplifications at sites of chromosome fission and fusion [56]. Moreover, we have shown 
previously that MYC-IGH fusion occurs in cNHL, and have detected constitutive MYC 
expression both in cDLBCL and cBKL [57]. aCGH data for ten cBCL cases overlapping 
with this prior study showed incomplete correlation between the DNA copy number status 
and transcriptional status of MYC (data not shown). This is consistent with findings in 
canine osteosarcoma [58] and lymphoid tumor cell lines [59], suggesting that multiple, 
complex mechanisms are involved in transcriptional control of this oncogene, and 
correlating with observations in human cBCL [60]. Interestingly, however, while MYC copy 
number increase is associated with BCL in human patients, in the present study there was no 
significant difference in the incidence of MYC gain when comparing cBCL (38.9% of 
cases) and cTCL (29.7% of cases) (p < 0.334). The profile of gain along the full length of 
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CFA 13 was strikingly similar in both cNHL phenotypes (figure 2), peaking in incidence at 
39.7Mb in cBCL and at 41.7Mb in cTCL (CFA 13q21.1), more than 10Mb distal to the 
MYC locus (CFA 13q13: 28.2Mb). These observations suggest that copy number gain of this 
oncogene is not the primary driving force for the recurrent gain in copy number of CFA 13 
in cNHL, and may be a consequence rather than a causative factor. Moreover it is apparent 
from a range of parallel studies that gain of CFA 13 is common to a spectrum of other 
canine cancers, including osteosarcoma, glial tumors, histiocytic sarcomas and prostate 
tumors [26,51,61-63 and our unpublished observations}. Our observations of CFA 13 gain 
in canine cancer patients therefore closely resemble those of HSA 7 gain in human patients, 
and suggest that cross-species analyses may aid with identification of recurrent CNAs that 
are more intimately associated with disease progression rather than initiation, and which 
may not be as fundamentally involved in tumor pathogenesis as their frequency may 
suggest.
In earlier studies we reported the identification of evolutionarily conserved chromosome 
aberrations that are shared by human and canine counterparts of the same spontaneous 
malignancy. These included MYC-IGH fusion in NHL, BCR-ABL fusion in chronic 
myelogenous leukemia, PTEN deletion in osteosarcoma, MYC gain in glioma and 
osteosarcoma, and deletion of RB in chronic lymphocytic leukemia [9,26,40,57,59,61, 
Angstadt et al. submitted]. The present study indicates that while the aCGH profiles of 
hNHL and cNHL share common features, there is limited conservation of the hallmark 
CNAs of each species. These findings are reminiscent of our prior report of intracranial 
tumors in the dog, in which we determined that canine meningiomas show negligible 
evidence for deletion of the NF2 tumor suppressor gene that is widely regarded as a 
hallmark of human meningiomas, while canine gliomas do not appear to present with CNAs 
orthologous to the deletions of HSA 1p and 19q that are characteristic of human glioma 
patients [26]. We suggested that the apparent contrast between the extensive histological and 
clinical similarity of canine and human tumors versus the lack of conservation in structural 
chromosome rearrangements might be related to their vastly contrasting genome 
architecture. In figures 3 and 4 it is apparent from our ‘genomic recoding’ approach that 
conversion of canine to human chromosome co-ordinates has the effect of visually 
‘disrupting’ the genome into smaller defined fragments at the subchromosomal level, 
resulting in a series of peaks and troughs in the resulting CNA penetrance plots. This 
fragmentation reflects the highly contrasting structural organization of the 200+ 
evolutionarily conserved chromosome segments shared by the human and canine genomes 
as a result of evolution from a common ancestral karyotype [14,15]. For example, CFA 11, 
recurrently deleted in cTCL, is orthologous to two regions (located on HSA 5 and 9) that 
show recurrent deletion in hTCL patients. Conversely gains of CFA 13 and 29 in cTCL 
correspond to neighboring syntenic chromosome segments forming the distal half of HSA 
8q, which is frequently gained in hTCL (reviewed in [44]). Comparison of genome 
organization in phylogenetically diverse species has shown that almost 20% of chromosome 
breakpoints were reused during mammalian evolution, many of which represent centromeric 
regions and are associated with higher than average gene density. The locations of antigen 
receptor genes and many other cancer-associated chromosome breakages correspond closely 
to evolutionary breakpoints, suggesting that they may be inherently fragile [64]. 
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Characterization of the genes disrupted by cancer-associated translocation events has been 
notoriously challenging using traditional cytogenetic approaches [56]. Thus cross-species 
genomics analysis offers exciting opportunities for expediting gene discovery by focused 
evaluation of genes located at evolutionary breakpoints.
Despite the apparently limited aneuploidy detected in cNHL, interrogation of recurrent 
CNAs identified in this study identified an extensive catalogue of chromosomal regions and 
genes presenting with recurrent DNA copy number imbalance in cNHL. Within these are 
key genes that have been associated previously with a range of human malignancies, while 
others highlight pertinent targets for focused evaluation in future studies. While conversion 
of our cDLBCL aCGH data into human genome format indicated a limited degree of global 
conservation in their cytogenetic profiles, a subset of common, evolutionarily conserved 
aberrations are evident. We propose that targeted analysis of these conserved CNAs will 
accelerate progress in defining the fundamental underlying molecular pathogenesis of these 
cancers in both species, and manipulating this knowledge to improve outcome. Recent 
advances in development of immunotherapeutic strategies that are effective across species 
[65] have shown great promise for a ‘one medicine’ approach to NHL. High-resolution 
cross-species cytogenomic analysis coupled with gene expression profiling of a common 
case series is now required in order to define and explore the most biologically relevant 
genomic parallels, to establish their functional role in tumor initiation and progression, and 
to evaluate their potential for targeted therapy in both human and canine patients.
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Distribution of cNHL cases by a) breed and tumor phenotype, and b) by histological 
subtype. Data for cBCL cases are denoted by blue shading, and for cTCL cases by red 
shading. A Fisher's exact test identified a highly significant association (p < 0.001) between 
breed and tumor phenotype. When all cases were stratified according to immunophenotype, 
the frequency of different histological subtypes showed no significant association with breed 
(p < 1.00 for BCL, p < 0.768 for TCL).
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Summary of recurrent genomic copy number imbalances in a) all 150 cNHL cases, b) the 
113 cBCL cases and c) the 37 cTCL cases. Each arrayed BAC clone is plotted against its 
chromosomal location along the x-axis. The y-axis indicates the percentage of the 
corresponding subset of the cNHL cohort that show demonstrated either copy number gain 
(shown in red above the midline) or copy number loss (shown in green below the midline) at 
each arrayed locus. Genes of specific interest are annotated and are discussed in the text. 
These data demonstrate the elevated degree of genomic instability associated with cTCL as 
compared to cBCL, and reveals two immunophenotype-associated chromosome copy 
number aberrations, located on CFA 11 and CFA 26.
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Comparison of recurrent genomic copy number imbalances in canine and human BCL. a) 
summarizes the genome-wide incidence of copy number gain and loss in the 80 cDLBCL 
cases from the present study, according to their dog chromosomal location. Gains of CFA 13 
and CFA 31 are highlighted in blue and pink, respectively. In b) the same canine data are 
replotted according to the equivalent location of arrayed loci on the corresponding human 
chromosome. When recoded into orthologous human genome co-ordinates, gain of CFA 13 
now manifests as partial gains on HSA 4 and 8 (highlighted in blue) and gain of CFA 31 
manifests as gain of HSA 21 (highlighted in pink). Figure c) shows data in a comparable 
format derived from a prior study of 46 hDLBCL cases [22]. In d) and e) these 46 hDLBCL 
cases are segregated to compare the cytogenetic profiles of the 28 hABC-DLBCL cases and 
the 18 hGCB-DLBCL cases, respectively. These images demonstrate the apparently reduced 
degree of genomic imbalance detected in cBCL compared to its human counterpart, and 
reveals evidence for shared aberrations (including gain of MYC) as well as aberrations that 
are not shared (such as deletion of CDKN2A/B).
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Comparison of recurrent genomic copy number imbalances in canine and human TCL. a) 
summarizes the genome-wide incidence of copy number gain and loss in the 18 cPTCLu 
cases from the present study, according to their dog chromosomal location. In b) the same 
data are recoded into human chromosome format. c) shows data in a comparable format 
derived from a prior study of 29 hPTCLu cases [23]. This comparison reveals that PTCLu is 
associated with extensive genomic instablility in both species, and identifies regions of 
evolutionarily shared imbalance, including deletion of CDKN2A/B.
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